AntifungalInteractions.org – A Specialist Resource for Safer Antifungal Treatment

Last reviewed: April 2026

Managing antifungal medications can be complex. Many antifungal drugs interact with other medicines, foods, and even supplements.
To support both patients and healthcare professionals, a dedicated resource is available:
AntifungalInteractions.org.


Key Points

  • A specialist database focused specifically on antifungal drug interactions
  • More detailed and targeted than general resources such as the British National Formulary (BNF)
  • Includes guidance designed for both healthcare professionals and patients
  • Regularly updated (typically several times per month)
  • Maintained by an experienced clinical pharmacist and prescriber
  • Owned and supported by the Fungal Infection Trust

What is AntifungalInteractions.org?

AntifungalInteractions.org is a dedicated online database designed to help users understand how antifungal medications interact with:

  • Other prescribed drugs
  • Over-the-counter medications
  • Herbal supplements
  • Certain foods and drinks

Unlike general drug reference tools, this resource focuses specifically on antifungal medicines, making it particularly useful for conditions such as aspergillosis, where treatment often involves long-term or complex therapy.


Why This Resource Matters

1. Antifungal drugs are complex

Common antifungal medications such as azoles (e.g. itraconazole, voriconazole, posaconazole) are known to interact with many other drugs.
These interactions can:

  • Increase side effects
  • Reduce treatment effectiveness
  • Require dose adjustments or monitoring

2. General resources may not go far enough

Widely used tools like the British National Formulary (BNF) are essential, but they are designed for broad use across all medicines.
AntifungalInteractions.org provides:

  • More detailed interaction explanations
  • Practical interpretation of risk
  • Condition-specific relevance

3. It supports informed discussions

The database is not a replacement for clinical advice, but it can help patients and clinicians:

  • Prepare for consultations
  • Understand potential risks
  • Ask more informed questions

Who Maintains the Database?

AntifungalInteractions.org is maintained by:

Saarah Niazi-Ali
MPharm, PG Cert (General Pharmacy Practice), PG Dip (Advanced Clinical Pharmacy Practice),
Independent Pharmacist Prescriber, Non-Medical Prescribing (Level 7), Final Medical Signatory

The database is updated frequently—typically 3–4 times per month, often on a weekly basis—ensuring that information remains current and clinically relevant.


Governance and Ownership

The resource is owned and supported by the Fungal Infection Trust, a UK-based organisation dedicated to improving the understanding, diagnosis, and treatment of fungal diseases.

This ensures that the database:

  • Remains focused on patient benefit
  • Is aligned with specialist fungal disease care
  • Supports both clinical practice and patient education

Who Is It For?

Patients and carers

  • To better understand their medications
  • To check for potential interactions
  • To support conversations with their clinical team

Healthcare professionals

  • Infectious disease specialists
  • Respiratory clinicians
  • Pharmacists
  • GPs managing complex patients

It is particularly valuable for clinicians managing conditions such as:

  • Chronic pulmonary aspergillosis (CPA)
  • Allergic bronchopulmonary aspergillosis (ABPA)
  • Other fungal infections requiring long-term antifungal therapy

How Does It Compare to Other Resources?

Feature AntifungalInteractions.org General Drug References (e.g. BNF)
Focus Antifungal-specific All medicines
Level of detail High (specialist) Moderate (broad coverage)
Patient-friendly explanations Yes Limited
Update frequency Frequent (monthly/weekly) Regular but broader scope

Important Notes for Patients

While this database is a valuable resource, it should be used appropriately:

  • Do not stop or change medication based on what you read
  • Always discuss concerns with your doctor, pharmacist, or specialist team
  • Use the information to support—not replace—medical advice

When to Seek Medical Advice

Contact your healthcare provider if you:

  • Start a new medication while on antifungal treatment
  • Experience new or worsening side effects
  • Are unsure whether a supplement or food is safe
  • Have been advised of a potential interaction

Summary

AntifungalInteractions.org is a highly valuable, specialist resource that fills an important gap in antifungal care.
Its combination of:

  • Expert clinical oversight
  • Frequent updates
  • Patient-accessible explanations
  • Specialist focus

makes it an important tool for both patients and healthcare professionals managing fungal disease.


Further Reading


Author & Review

Prepared for Aspergillosis patient and healthcare education.
Content aligned with UK specialist practice and reviewed for clarity and safety.


Aspergillosis and Diet: coping with weight loss, poor appetite, food avoidance and stomach symptoms

For: patients, carers, general practitioners, specialist nurses and other non-specialists


Key points

  • Eating difficulties are common in aspergillosis, especially in chronic pulmonary aspergillosis (CPA) and in people who also have other lung disease.
  • The problem is often not simply “poor appetite”. Breathlessness, cough, fatigue, reflux, nausea, altered taste and medicine side effects can all make eating difficult.
  • Some people gradually cut out more and more foods because eating feels uncomfortable or because they have been told certain foods are “bad” for lung symptoms.
  • For many patients, the main nutritional goal is not a “perfect” diet. It is getting enough energy, protein and fluids in ways that feel manageable.
  • “Little and often”, food fortification and nourishing drinks are often more realistic than trying to eat three large meals a day.
  • Ongoing weight loss, a very restricted diet, persistent nausea, reflux or difficulty eating most days should be discussed with a doctor, specialist team or dietitian.


Why diet can become a major problem in aspergillosis

Many people living with aspergillosis find that eating becomes much harder than it used to be. This is particularly important in chronic pulmonary aspergillosis (CPA), where weight loss, fatigue and general ill health are common features of the illness. In practical terms, the body may need more energy while the person is less able to eat comfortably.

Several problems can overlap:

  • Breathing takes more effort, which can increase energy needs.
  • Coughing or breathlessness can interrupt meals.
  • Tiredness can make shopping, cooking and eating feel like hard work.
  • Inflammation and chronic illness can reduce appetite and contribute to muscle loss.
  • Antifungal treatment and other medicines can cause nausea, altered taste, indigestion or poor appetite.
  • Reflux, bloating or early fullness may mean that even small meals feel uncomfortable.

For some patients this creates a vicious circle: eating becomes unpleasant, intake falls, weight drops, strength falls, and eating may then feel even more difficult.

Who is most affected?

Not every patient with aspergillosis has major nutritional problems, but some groups are more likely to struggle. This includes people with:

  • Chronic pulmonary aspergillosis (CPA)
  • pre-existing lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis or previous tuberculosis
  • long-term fatigue, breathlessness or coughing
  • persistent nausea or reflux symptoms
  • a history of recent unplanned weight loss
  • side effects from antifungal or other medicines
  • anxiety around eating because meals repeatedly trigger symptoms

Some people with allergic bronchopulmonary aspergillosis (ABPA) also report poor intake or nutritional difficulties, although the pattern may differ from CPA. In ABPA, steroid treatment, asthma burden, medicine effects and general symptom load may all influence diet.

How eating can become difficult

People often describe eating problems in ways that do not sound like a classic “nutrition” issue. They may say things like:

  • “I get full after a few mouthfuls.”
  • “I cannot face a proper meal.”
  • “Eating makes me cough.”
  • “I feel uncomfortable after food.”
  • “Some foods seem to sit badly.”
  • “I only eat a few safe foods now.”

These experiences are important. They suggest that the real problem may be a mixture of breathlessness, upper gastrointestinal symptoms, medicine effects and learned food avoidance, not simply a lack of willpower or poor food choices.

When eating shrinks into a “minimal diet”

Some patients end up eating very little, often because that feels safer or more manageable than trying to eat normally. A “minimal diet” may look like:

  • very small amounts of food only once or twice a day
  • mostly soft or liquid foods
  • reliance on tea, toast, soup or yoghurt
  • long gaps without eating
  • skipping meals because eating feels exhausting

This is understandable, but it can become a serious problem. Small intake over time may lead to:

  • weight loss
  • loss of muscle mass
  • greater weakness and fatigue
  • slower recovery from illness
  • reduced ability to cope with infections or treatment

If a patient is managing only tiny amounts of food, the first goal is often not to rebuild a “normal” diet immediately. It is to make intake easier, more comfortable and more nourishing.

Avoiding many food types

Another common pattern is gradual food restriction. Patients may stop eating several food groups because they believe these foods worsen mucus, cough, reflux, nausea or fungal disease.

Examples include avoiding:

  • dairy products
  • sweet foods
  • bread or dry foods
  • meat
  • acidic foods
  • foods linked in the mind to a previous bad episode

Sometimes there is a genuine reason for avoiding a particular food. For example, reflux may make acidic or very fatty foods uncomfortable, and a dry crumbly food may clearly trigger coughing. The difficulty is that repeated bad experiences can also lead to over-restriction, where more and more foods are cut out than is really necessary.

That can leave the diet low in calories, low in protein and very repetitive. In practice, the aim is usually to adapt foods rather than cut out whole food groups unless there is a clear reason to avoid them.

Could the stomach or gut be part of the problem?

Yes. This is often overlooked.

Some patients with aspergillosis describe symptoms that sound mainly digestive rather than respiratory, for example:

  • nausea
  • heartburn or reflux
  • bloating
  • feeling full very quickly
  • upper abdominal discomfort
  • reduced appetite after starting or changing medication
  • alternating diarrhoea and constipation

There are several possible reasons:

  • Medicine side effects, including antifungals
  • Gastro-oesophageal reflux disease (GORD), which can also worsen cough
  • reduced activity levels and chronic illness
  • constipation, especially when intake is poor or medicines contribute
  • co-existing gastrointestinal disease that is separate from aspergillosis

If eating repeatedly causes upper abdominal or chest discomfort, or if reflux and nausea are prominent, it is reasonable to think of this as a symptom needing review rather than simply a “fussy eating” problem.

Practical ways to make eating easier

Different things help different people, but these approaches are often more realistic than trying to push through large meals.

1. Think “little and often”

Many people do better with five or six small eating opportunities through the day instead of three big meals. That may mean a small breakfast, a mid-morning snack, a light lunch, a nourishing drink, an evening meal and a supper snack.

2. Lower the effort of eating

Soft, moist foods are often easier than dry, chewy or crumbly foods. Examples include:

  • porridge
  • yoghurt
  • custard or rice pudding
  • mashed potato with added butter or cheese
  • scrambled eggs
  • soup with cream or grated cheese
  • stews, casseroles or sauced dishes

3. Use drinks as nutrition

For some patients, drinks are easier to manage than food. Nourishing options can include:

  • milky drinks
  • smoothies
  • milkshakes
  • fortified hot drinks
  • commercial oral nutritional supplements if prescribed or advised

4. Rest before eating

If fatigue or breathlessness are major barriers, it can help to eat after a rest rather than after exertion. Some people find breakfast or lunch easier than an evening meal.

5. Sit upright and stay upright afterwards

This can be especially helpful when reflux, coughing or chest discomfort are part of the picture.

6. Slow the pace

It is acceptable to eat slowly and pause often. Some patients benefit from smaller mouthfuls and short breathing pauses between them.

7. Look for manageable variety

If the diet has become very narrow, widening it gently may be more successful than trying to overhaul everything at once.

How to support weight maintenance

When keeping weight on is difficult, the most useful approach is often to increase the energy and protein content of what is already being tolerated.

Food-first ideas

  • Add butter, cream, cheese, yoghurt, milk powder or olive oil to foods where suitable.
  • Choose full-fat products rather than “diet” versions if weight loss is a concern.
  • Add grated cheese to soup, mashed potato, scrambled eggs or vegetables.
  • Make porridge with milk rather than water.
  • Keep easy snacks available, such as yoghurts, cheese and crackers, peanut butter, hummus, custard, rice pudding or milky desserts.

Protein matters

Protein helps preserve muscle. Good sources include:

  • milk, yoghurt and cheese
  • eggs
  • meat, fish and poultry if tolerated
  • beans, lentils and other pulses
  • nut butters where suitable

Oral nutritional supplements

When food alone is not enough, a doctor or dietitian may suggest oral nutritional supplements. These are often used between meals rather than instead of meals. They can be particularly helpful when appetite is low or meal size is very limited.

In general UK nutrition practice, a “food first” approach is usually tried first where appropriate, but oral nutritional supplements are commonly used when someone is at higher risk of malnutrition or is unable to meet needs from food alone.

Food and medicine issues to remember

Food and medicine can interact in two main ways.

1. Medicines can affect eating

Antifungal treatment and other medicines may contribute to:

  • nausea
  • indigestion
  • altered taste
  • poor appetite
  • bowel upset

If these symptoms started after a medicine was introduced or changed, it is worth discussing that with the prescribing team.

2. Food can affect medicines

Some antifungal medicines have specific instructions about when to take them in relation to food. For example:

  • Itraconazole capsules are generally taken with or just after food, while itraconazole liquid is generally taken on an empty stomach.
  • Voriconazole is usually taken on an empty stomach.
  • Some medicines also have important interactions with antacids or acid-suppressing medicines.

Because formulations differ, and because other medicines may also interact, patients should follow the instructions they have been given for their exact preparation and check with a pharmacist or clinical team if unsure.

Grapefruit and other food interactions: some medicines have clinically important food interactions. Patients should check current advice for each medicine rather than relying on memory or online generalisations.

Common diet myths

Dairy always makes mucus worse

This is a very common belief. Current evidence does not show that dairy routinely increases lung mucus production for most people. Some people do notice a thicker mouth or throat feeling after milk, which may relate to texture rather than extra mucus. If dairy is well tolerated, it can be a useful source of calories and protein.

Sugar “feeds” aspergillosis, so it should be cut out completely

Patients often hear this online, but strict self-imposed restriction can be more harmful than helpful when someone is already struggling to maintain intake. For many patients with weight loss, the immediate nutritional priority is adequate calories and protein, not aggressive dietary exclusion.

There is a special anti-aspergillosis diet

There is no widely accepted specialist diet that treats aspergillosis itself. In routine practice, nutrition advice usually focuses on preventing or treating malnutrition, easing symptoms and managing medicine-related issues.

If eating is difficult, I should just avoid more foods

Sometimes a food really is hard to tolerate, but repeated restriction can shrink the diet too far. Often it is more useful to ask, “Can this be made easier to eat?” rather than “Should I cut this out altogether?”

When to seek medical help

Patients should speak to their doctor, specialist team or another qualified healthcare professional if they have any of the following:

  • ongoing unplanned weight loss
  • clothes, rings or dentures becoming looser
  • difficulty eating most days
  • a very narrow diet with only a few “safe” foods
  • persistent nausea, reflux, bloating or abdominal discomfort
  • increasing weakness or fatigue
  • concerns that medicines are worsening appetite or stomach symptoms

It may be appropriate to ask about a dietitian referral, especially if intake has been poor for some time or there are signs of malnutrition.

Seek urgent medical advice if:

  • food or fluids are being kept down very poorly
  • there are signs of dehydration
  • weight loss is rapid or severe
  • pain, vomiting, swallowing difficulty or other worrying symptoms are developing

Common questions

Should I force myself to eat full meals?

Usually not. If full meals are consistently overwhelming, smaller and more frequent intake is often more successful.

Are liquid calories “cheating”?

No. For some people, nourishing drinks are one of the most practical ways to protect weight and strength.

What if I only manage a few foods?

That is still worth discussing. A restricted diet may be understandable, but it can increase nutritional risk over time.

What if dairy feels unpleasant?

Individual experience matters. If a food clearly feels uncomfortable, it may help to try alternatives or use smaller amounts in different forms. But many people do not need to exclude dairy automatically.

Could reflux be making my cough worse?

Yes, it can in some people. Reflux can irritate the upper airway and may contribute to cough or discomfort around meals.

When to seek medical advice

Ask for medical advice if you are losing weight, struggling to eat most days, developing a very restricted diet, or think nausea, reflux or medication side effects are affecting your intake. Ask urgently if you are becoming dehydrated, vomiting repeatedly, or your intake has become extremely poor.

Author and review information

Prepared for: aspergillosis.org

Purpose: general educational information for patients and non-specialists

Review note: Because medicine instructions can change between formulations and brands, patients should always check the current advice supplied with their own prescription and confirm uncertainties with a pharmacist or clinical team.

References and further reading

  1. Carter C, Muldoon EG, Kosmidis C. Chronic pulmonary aspergillosis - a guide for the general physician. 2024.
    PubMed
  2. Tashiro M, Takazono T, Izumikawa K. Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, diagnosis, treatment, and unresolved challenges. 2024.
    Free full text
  3. Roboubi A, et al. Allergic bronchopulmonary aspergillosis. 2023.
    PubMed
  4. Sunman B, et al. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. 2020.
    Free full text
  5. Madhavan V, et al. Malnutrition in allergic bronchopulmonary aspergillosis complicating asthma. 2023.
    Free full text
  6. British Dietetic Association. Spotting and treating malnutrition.
    BDA resource
  7. BAPEN. Food first / food enrichment.
    BAPEN resource
  8. BAPEN / Malnutrition Pathway. Managing malnutrition in COPD.
    PDF
  9. NICE. Managing malnutrition in COPD, The Malnutrition Pathway.
    NICE shared learning resource
  10. NHS. Heartburn and acid reflux.
    NHS advice
  11. Cambridge University Hospitals NHS Foundation Trust. Dietary and lifestyle advice for adults with gastro-oesophageal reflux disease (GORD).
    CUH advice
  12. NICE BNF. Itraconazole.
    BNF drug monograph
  13. Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Itraconazole.
    PDF
  14. Manchester University NHS Foundation Trust, National Aspergillosis Centre. Patient Information: Voriconazole.
    PDF
  15. Oxford University Hospitals NHS Foundation Trust. Advice about antifungals.
    PDF
  16. Balfour-Lynn IM. Milk, mucus and myths. Archives of Disease in Childhood. 2019.
    Article
  17. Pinnock CB, Graham NM, Mylvaganam A. Relationship between milk intake and mucus production in adult volunteers challenged with rhinovirus-2. 1990.
    PubMed
  18. ASCIA. Milk, mucus and cough.
    Patient resource

Cystic Fibrosis, CFTR Gene Variants, and Aspergillosis

Last reviewed: 8 April 2026

Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.

This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.

Contents


Key points

  • Most people with aspergillosis do not have cystic fibrosis.
  • Most people with cystic fibrosis do not develop ABPA or CPA.
  • ABPA is linked to mucus and immune responses, not just infection.
  • CFTR variants may contribute to risk in some people, but are usually only one factor.
  • CPA is mainly driven by structural lung damage, not CFTR genetics.

Back to top ↑


Important reassurance

Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.

Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.

Back to top ↑


What is cystic fibrosis?

Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.

When CFTR function is reduced:

  • mucus becomes thick and sticky
  • airways are harder to clear
  • microorganisms persist more easily

This creates an environment where bacteria and fungi can accumulate over time.

Back to top ↑


What is a CFTR gene variant?

CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.

Carriers (with one variant):

  • are common in the general population
  • usually have no symptoms
  • may have subtle effects in some cases

These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.

Back to top ↑


How CFTR affects the lungs

CFTR dysfunction affects the lungs in several key ways:

  • Mucus dehydration: mucus becomes thick and difficult to clear
  • Impaired clearance: particles and microbes remain in the airways
  • Chronic inflammation: immune responses become exaggerated

This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.

Back to top ↑


How Aspergillus behaves in the lungs

Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.

  • Healthy lungs: spores are cleared
  • Impaired clearance: spores may persist
  • Sensitive immune system: allergic reactions may develop
  • Damaged lungs: chronic infection may develop

This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.

Back to top ↑


ABPA and cystic fibrosis

ABPA is an allergic immune reaction to Aspergillus.

It is recognised in cystic fibrosis because:

  • mucus retention increases exposure to Aspergillus
  • immune responses can be exaggerated

However:

  • Many CF patients never develop ABPA
  • Most ABPA patients do not have CF

Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.

Key message: ABPA and CF can overlap, but one does not imply the other.

Back to top ↑


CPA and cystic fibrosis

CPA is a chronic fungal infection that develops in structurally damaged lungs.

The most important risk factor is:

pre-existing lung damage

This includes:

  • bronchiectasis
  • previous tuberculosis
  • COPD

Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.

However:

  • CPA is rarely driven directly by CFTR genetics
  • most CPA patients do not have CF

Key message: CPA is primarily a disease of lung structure, not genetics.

Back to top ↑


Modern CF treatments and Aspergillus

CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.

They:

  • improve CFTR function
  • thin mucus
  • improve clearance

Studies suggest:

  • reduced Aspergillus detection in some patients
  • fewer ABPA exacerbations in some cases

However:

  • ABPA still occurs
  • existing lung damage remains
  • immune responses are not fully corrected

Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.

Back to top ↑


Does a CFTR variant explain symptoms?

No single factor explains complex lung disease.

Symptoms may result from:

  • underlying lung disease
  • infection
  • inflammation
  • environmental exposure

A CFTR variant may contribute, but is rarely the sole cause.

Back to top ↑


What should patients take from this?

  • CF and CFTR variants can sometimes contribute
  • ABPA has the strongest connection
  • CPA is mainly driven by lung damage
  • Most patients with aspergillosis do not have CF

Back to top ↑


When to seek medical advice

Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.

Back to top ↑


Conclusion

Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.

Back to top ↑


References

This article is for general information and does not replace advice from your clinical team.


Voriconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Voriconazole interacts with many medicines.
  • It affects several liver enzyme pathways, including CYP3A4, CYP2C19, and CYP2C9.
  • Its behaviour can vary more from one person to another than some other azoles.
  • Some medicines can make voriconazole stronger, while others can make it less effective.
  • Visual side effects and sensitivity to sunlight are well recognised with voriconazole.

What is voriconazole?

Voriconazole is an azole antifungal often used in serious fungal infections, including aspergillosis. It can be very effective, but it also has a relatively complex interaction profile.

Why voriconazole interacts with so many medicines

Voriconazole affects several liver enzyme systems, including CYP3A4, CYP2C19, and CYP2C9. It can increase the levels of some medicines, while some other medicines can lower voriconazole levels and reduce its effectiveness.

Because voriconazole metabolism varies between patients, the same combination can affect people differently.

The interaction groups most likely to matter

Steroids

Voriconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.

Medicines that reduce voriconazole levels

Some medicines, including certain anti-seizure medicines and rifampicin-type antibiotics, can reduce voriconazole levels so much that the antifungal may not work properly.

Blood thinners

Some blood thinners may become stronger when taken with voriconazole, increasing bleeding risk.

Heart rhythm medicines

Voriconazole can contribute to QT prolongation, so combinations with other medicines that affect heart rhythm may be particularly important.

Statins

Some statins can become stronger when taken with voriconazole, increasing the risk of muscle side effects.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly with voriconazole and often require specialist monitoring and dose adjustment.

Sedatives and some mental health medicines

Some sedatives and psychiatric medicines can become stronger when combined with voriconazole, increasing the risk of drowsiness, confusion, or other side effects.

Voriconazole-specific issues patients should know

Visual changes

Temporary visual disturbances are well recognised with voriconazole. Patients may notice blurred vision, brighter vision, or changes in colour perception.

Photosensitivity

Voriconazole can increase sensitivity to sunlight. Patients should use sensible sun protection and report new skin changes, especially during long-term treatment.

Variable drug levels

Voriconazole levels can vary between patients, which is one reason some teams use therapeutic drug monitoring in selected situations.

What patients should do in practice

  • Tell your clinical team and pharmacist that you are taking voriconazole.
  • Check before starting new medicines, including over-the-counter or herbal products.
  • Report visual changes, significant sensitivity to sunlight, or a change in symptoms after a medicine change.
  • Do not change treatment without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, severe palpitations, marked confusion, or rapid worsening after a medicine change.

Important

This page is educational and does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Itraconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Itraconazole can interact with many other medicines.
  • It usually does this by affecting liver enzymes, especially CYP3A4.
  • Some combinations need careful monitoring, while others are best avoided.
  • Capsules and liquid formulations are not handled by the body in exactly the same way.
  • This page highlights the interactions most likely to matter to people with aspergillosis.

What is itraconazole?

Itraconazole is an azole antifungal used in aspergillosis and other fungal infections. It has a relatively high interaction burden, so medicine checks are especially important before starting it and whenever another medicine is added, stopped, or changed.

Why itraconazole interacts with so many medicines

Itraconazole can increase the levels of some other medicines by affecting liver enzymes, especially CYP3A4. This means that some medicines may become stronger than intended, which can increase the risk of side effects or toxicity.

The interaction groups most likely to matter

Steroids and inhalers

This is one of the most important groups for many aspergillosis patients, especially those with asthma or allergic bronchopulmonary aspergillosis. Itraconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.

Possible symptoms to report: unusual weight gain, easy bruising, increased facial rounding, mood changes, worsening blood sugar control, weakness, or marked fatigue.

Statins

Some statins can become much stronger when taken with itraconazole. This can increase the risk of muscle toxicity.

Possible symptoms to report: new muscle pain, muscle weakness, or dark urine.

Blood thinners

Itraconazole can increase the effect of some blood thinners, which may raise bleeding risk.

Possible symptoms to report: unusual bruising, bleeding that is hard to stop, black stools, vomiting blood, or coughing up much more blood than usual.

Heart and rhythm medicines

Some combinations can increase the risk of serious heart rhythm problems. Itraconazole is also used cautiously in people with a history of ventricular dysfunction or heart failure unless the infection is serious.

Possible symptoms to report: fainting, palpitations, marked dizziness, increasing ankle swelling, or worsening breathlessness.

Sleeping tablets, sedatives, and some mental health medicines

Some sedatives and psychotropic medicines can become stronger when combined with itraconazole, increasing the risk of drowsiness, confusion, falls, or breathing problems.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly when taken with itraconazole and usually need specialist monitoring.

Medicines that can make itraconazole less effective

Some medicines lower itraconazole levels, which means the antifungal may not work as well. This can happen with some anti-seizure medicines, rifampicin-type antibiotics, and some antiviral medicines.

Acid-reducing medicines and itraconazole capsules

Reduced stomach acid can lower the absorption of itraconazole capsules. This means reflux medicines, antacids, and some acid-suppressing treatments can affect how well the capsules work. The liquid formulation behaves differently and should not be treated as interchangeable with capsules.

What patients should do in practice

  • Keep a current medicines list and bring it to appointments.
  • Tell clinicians and pharmacists if you are taking itraconazole.
  • Ask specifically about inhalers, steroid tablets, statins, blood thinners, and reflux treatment.
  • Do not change doses or stop medicines without advice.
  • If your itraconazole formulation changes, ask whether it should be taken with food or on an empty stomach.

When to seek medical advice

Seek urgent medical advice for severe bleeding, black stools, vomiting blood, severe muscle pain, fainting, marked palpitations, or rapidly worsening breathlessness.

Important

This page is not a full interaction database. For a complete medicine-by-medicine check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Amphotericin B interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Amphotericin B comes in different formulations, and they are not interchangeable.
  • Its main interaction risks are different from the azoles.
  • The most important problems are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines.
  • These risks matter most with intravenous treatment.
  • If you hear “amphotericin B”, it is important to know which formulation is being used.

What is amphotericin B?

Amphotericin B is an antifungal used mainly for serious fungal infections. In modern UK practice this often means liposomal amphotericin B, but conventional amphotericin B deoxycholate is also a recognised formulation.

Why amphotericin B interactions are different from azoles

Unlike azole antifungals, amphotericin B does not mainly cause medicine interactions through liver enzymes. Its most important interaction risks usually relate to kidney injury, low potassium, low magnesium, and infusion-related effects.

The interaction groups most likely to matter

Other medicines that can damage the kidneys

This is one of the most important groups. Combining amphotericin B with other nephrotoxic medicines can increase the risk of kidney injury.

Diuretics, steroids, and other medicines that lower potassium

Amphotericin B can lower potassium, and some other medicines can make this worse. This may increase the risk of weakness, cramps, or heart rhythm problems.

Digoxin and heart-rhythm-sensitive situations

Low potassium caused by amphotericin B can make digoxin-related toxicity more likely and may increase the importance of electrolyte monitoring.

Flucytosine

When combined with flucytosine, specialist monitoring may be needed because toxicity can increase.

Some cancer medicines and intensive hospital treatments

In hospital, additive toxicity with other intensive treatments may be particularly important, especially where kidneys and electrolytes are already under strain.

White blood cell transfusions

Acute lung reactions are a recognised specialist concern if amphotericin B is given during or soon after leukocyte transfusions.

Why the formulations matter

Amphotericin B formulations are not interchangeable. Conventional amphotericin B deoxycholate and liposomal amphotericin B have different dosing, different handling by the body, and different safety profiles. Using the wrong formulation in the wrong dose has caused serious and even fatal errors.

In general, liposomal amphotericin B is less nephrotoxic than conventional amphotericin B deoxycholate, but it still requires careful monitoring.

What patients should do in practice

  • Ask which amphotericin B formulation is being used.
  • Tell the clinical team about all medicines, especially kidney-risk medicines, diuretics, steroids, and digoxin.
  • Expect blood tests to monitor kidney function, potassium, and magnesium during intravenous treatment.
  • Report weakness, reduced urine output, worsening swelling, palpitations, or marked dizziness.

When to seek medical advice

Seek urgent medical help for severe breathlessness, fainting, major palpitations, or a rapid deterioration during treatment.

Important

This page is educational and does not list every possible interaction. Amphotericin B treatment is usually managed by specialist teams, especially when given intravenously.

References


Isavuconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Isavuconazole can interact with other medicines, but its interaction profile is often less complex than older azoles.
  • It mainly interacts through CYP3A4.
  • Some medicines can increase isavuconazole levels, while others can reduce its effectiveness.
  • It has an important difference from some other azoles: it can shorten the QT interval.
  • It is still essential to check new medicines carefully.

What is isavuconazole?

Isavuconazole is a newer azole antifungal used in invasive aspergillosis and some other serious fungal infections. It is often seen as having a more predictable interaction profile than some older azoles, but it still has important interactions.

Why isavuconazole interacts with other medicines

Isavuconazole is mainly linked to CYP3A4. This means some medicines can become stronger when combined with it, while other medicines can lower isavuconazole levels and reduce its effectiveness.

The interaction groups most likely to matter

Medicines that reduce isavuconazole effectiveness

Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower isavuconazole levels and may make treatment ineffective.

Steroids

Some steroid levels may rise with isavuconazole, although the interaction pattern is often less intense than with some older azoles.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin may increase and usually need specialist review and monitoring.

Blood thinners

Some blood thinners may become stronger, increasing bleeding risk.

Statins

Some statin levels may increase, which can raise the risk of muscle side effects.

Important isavuconazole-specific points

QT shortening

Unlike several other azole antifungals, isavuconazole can shorten the QT interval. This is an important difference and should be considered when other heart medicines are being reviewed.

Generally simpler interaction profile

Compared with itraconazole and voriconazole, isavuconazole is often considered a little easier to manage in patients taking several medicines, although checks are still essential.

What patients should do in practice

  • Tell your pharmacist or clinician if you are taking isavuconazole.
  • Check before starting prescription, over-the-counter, or herbal medicines.
  • Ask specifically about anti-seizure drugs, antibiotics, blood thinners, and heart medicines.
  • Do not stop or change medicines without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, severe palpitations, severe muscle pain, or rapid worsening after a medicine change.

Important

This page is educational and not a complete interaction database. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Posaconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Posaconazole can interact with other medicines, although its interaction pattern is often a little simpler than itraconazole or voriconazole.
  • It mainly interacts through CYP3A4 inhibition.
  • Important interaction groups include immunosuppressants, steroids, blood thinners, and some heart medicines.
  • Some medicines can reduce posaconazole levels and make treatment less effective.
  • Tablets and oral suspension are not interchangeable in the same way.

What is posaconazole?

Posaconazole is an azole antifungal used in aspergillosis and in some high-risk patients for prevention of fungal infection. It is often seen as somewhat easier to manage than some older azoles, but important interactions still exist.

Why posaconazole interacts with other medicines

Posaconazole mainly affects CYP3A4, a key liver enzyme involved in handling many medicines. This means some drugs can become stronger, while some combinations can lower posaconazole levels and make it less effective.

The interaction groups most likely to matter

Steroids

Posaconazole can increase exposure to some steroids, including inhaled or oral steroids, which may increase the risk of steroid side effects.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly with posaconazole and usually need close specialist monitoring.

Blood thinners

Some blood thinners may become stronger, increasing bleeding risk.

Statins

Some statins can rise in level, increasing the risk of muscle problems.

Heart rhythm medicines

Some combinations can increase the risk of heart rhythm problems and need careful review.

Medicines that reduce posaconazole effectiveness

Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower posaconazole levels and may make treatment less effective.

Posaconazole formulations and absorption

Posaconazole comes in different forms, including tablets, oral suspension, and infusion. The oral suspension and tablets are not handled identically by the body and should not be assumed to be interchangeable dose-for-dose without clinical advice.

In practice, the tablets tend to be more predictable than the suspension.

What patients should do in practice

  • Tell your pharmacist or clinician if you are taking posaconazole.
  • Ask about new medicines, especially blood thinners, steroids, statins, and heart medicines.
  • If your formulation changes, ask whether there are any special instructions.
  • Do not stop or swap medicines without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, major palpitations, severe muscle pain, or rapid worsening after a medicine change.

Important

This page does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Antifungal drug interactions: what patients with aspergillosis need to know

Last reviewed: April 2026

Key points

  • Antifungal medicines can interact with other medicines, including inhalers, steroid tablets, blood thinners, heart medicines, cholesterol tablets, and some over-the-counter or herbal products.
  • The azole antifungals usually interact by affecting how the liver handles medicines.
  • Amphotericin B is different: its main interaction risks are more often linked to kidneys, potassium, magnesium, and infusion-related effects.
  • This page gives an overview. It does not list every interaction.
  • For a full medicine-by-medicine check, use the BNF interaction checker or ask a pharmacist or clinician.

Why interactions matter in aspergillosis

People with aspergillosis often take more than one medicine. This may include inhalers, steroid tablets, medicines for reflux, antibiotics, pain relief, blood pressure treatment, blood thinners, cholesterol tablets, and drugs for other long-term conditions. That means medicine checks are especially important whenever an antifungal is started, stopped, or changed.

How the main antifungals differ

Most long-term interaction questions in aspergillosis involve the azole antifungals: itraconazole, voriconazole, posaconazole, and isavuconazole. These mainly interact because they affect liver enzymes, especially CYP3A4, although some also affect CYP2C9 and CYP2C19.

Amphotericin B behaves differently. Its most important risks are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines rather than classic liver-enzyme interactions.

Quick comparison table

Antifungal Main interaction pattern Typical complexity Important extra point
Itraconazole Strong enzyme-based interactions, especially CYP3A4 High Capsules and liquid are not handled by the body in the same way
Voriconazole Complex enzyme-based interactions involving several CYP pathways High More variable between patients; visual side effects and photosensitivity are well recognised
Posaconazole Mainly CYP3A4-related interactions Moderate Tablets and oral suspension are not interchangeable in the same way
Isavuconazole Mainly CYP3A4-related interactions, usually less complex than older azoles Lower to moderate Can shorten the QT interval
Amphotericin B Kidney, potassium, magnesium, and infusion-related interaction risks Different rather than simpler Formulations are not interchangeable

Individual antifungal guides

What patients should do in practice

  • Keep an up-to-date list of all medicines, including inhalers, creams, over-the-counter medicines, supplements, and herbal products.
  • Tell your doctor, nurse, pharmacist, or hospital team that you are taking an antifungal.
  • Do not start, stop, or swap medicines on your own because of something you have read online.
  • Ask specifically about new medicines, steroid changes, reflux treatment, blood thinners, cholesterol medicines, and heart medicines.

When to seek medical advice

Seek medical advice promptly if symptoms change after a medicine is started, stopped, or changed. Seek urgent help for severe bleeding, fainting, severe muscle pain, marked palpitations, rapidly worsening breathlessness, severe drowsiness, or a sudden significant decline in your health.

Important

This resource is educational. It does not replace personalised advice from your clinical team, GP, or pharmacist, and it is not a complete interaction database.

References


Why Headaches Can Occur in Aspergillosis

Last reviewed: March 2026

Key Points

  • Headaches are relatively common in people living with aspergillosis, but they usually have multiple contributing causes.
  • Common causes include sinus involvement, inflammation, sleep disturbance, and medication effects.
  • Antifungal medicines such as itraconazole may improve some symptoms indirectly but can also occasionally cause headaches.
  • Patterns (timing, location, triggers) can help identify likely causes, but headaches are rarely due to one factor alone.
  • New, severe, or unusual headaches should always be assessed by a healthcare professional.

Table of Contents

Overview

Many people living with aspergillosis report headaches at some point during their illness. These headaches can vary in type, severity, and timing, and may be confusing—especially when they change over time or seem linked to treatment.

In most cases, headaches are not caused by a single factor. Instead, they reflect a combination of:

  • local effects (such as sinus pressure)
  • immune system activity
  • medication effects
  • sleep and general health factors

Understanding these different contributors can help make sense of symptoms and support more informed discussions with your clinical team.

Sinus involvement (common cause)

When Aspergillus affects the sinuses (sometimes called fungal sinusitis), this can directly cause headaches.

This happens because:

  • sinus drainage becomes blocked
  • pressure builds up in the sinus cavities
  • the lining of the sinuses becomes inflamed

Typical features:

  • pain or pressure in the forehead, cheeks, or behind the eyes
  • worsening when bending forward
  • a feeling of fullness or congestion

This is one of the most direct ways aspergillosis can lead to headaches.

Inflammation and immune response

Even when the sinuses are not directly involved, the body’s immune response to fungal material can cause systemic effects.

The immune system releases signalling molecules (such as cytokines) that can:

  • increase inflammation
  • affect blood vessels
  • trigger headache pathways

This type of headache can feel similar to a “flu-like” or inflammatory headache.

Allergic-type responses (e.g. ABPA)

In conditions such as Allergic Bronchopulmonary Aspergillosis (ABPA), the immune system reacts strongly to Aspergillus.

This may involve:

  • allergic pathways
  • histamine and related mediators
  • ongoing airway inflammation

Possible symptoms:

  • head pressure or discomfort
  • fluctuating headaches
  • a “foggy” or unwell feeling

These headaches are often less clearly localised than sinus-related pain.

Medication effects

Some treatments used in aspergillosis can contribute to headaches.

Antifungal medications (e.g. itraconazole):

  • headache is a recognised side effect in some people
  • effects vary between individuals

Steroids (if prescribed):

  • can affect sleep and mood
  • may influence blood pressure
  • can indirectly contribute to headaches

Medication effects can sometimes overlap with disease-related symptoms, making patterns harder to interpret.

Sleep disturbance and night symptoms

Sleep disruption is common in chronic lung conditions.

Possible contributors include:

  • night-time coughing
  • breathlessness
  • discomfort or anxiety

Poor sleep can lead to:

  • morning headaches
  • increased sensitivity to pain
  • fatigue-related headaches

Breathing and oxygen levels

In some people with more advanced lung involvement:

  • oxygen levels may be slightly reduced
  • breathing effort may increase

This can contribute to:

  • morning headaches
  • fatigue and cognitive symptoms

Not all patients experience this, but it is an important factor in some cases.

General health factors

Headaches can also be influenced by general aspects of living with a long-term condition:

  • dehydration
  • fatigue
  • reduced activity levels
  • stress or anxiety

These factors can contribute to tension-type headaches or make other headache types more noticeable.

Understanding headache patterns

Looking at patterns can sometimes help identify likely contributors.

  • Facial pressure worse on bending: may suggest sinus involvement
  • Early morning headaches: may relate to sleep or breathing patterns
  • Fluctuating or “wave-like” symptoms: may reflect inflammation or immune activity
  • New headaches after starting medication: may be treatment-related

However, these are general observations only and do not replace clinical assessment.

Headaches in Aspergillosis: Interactive Decision Aid

This tool helps patients and carers think about common patterns that can contribute to headaches in aspergillosis. It does not diagnose the cause of a headache.

It is designed to support discussion with a healthcare professional and highlight possible contributors such as sinus involvement, inflammation, medication effects, sleep disturbance, and breathing-related factors.

Important: This tool is for general information only. It cannot determine the cause of an individual’s symptoms and does not replace medical advice. If you are concerned about headaches or changes in symptoms, please speak to your healthcare team.

1. Where is the pain mainly felt?



2. When is it most noticeable?



3. What does it feel like?



4. What other features are present?






5. Are there any red flags?



Possible contributors

This panel highlights common patterns only. It is not a diagnosis and does not replace medical assessment.

These are possible patterns only and are not a diagnosis.
This tool is intended to support discussion and reflection. If your headaches are new, worsening, or concerning, speak to your healthcare team.
Select your answers and click Show possible contributors.

Common questions

Are headaches a recognised symptom of aspergillosis?

They can occur, but are usually indirect and caused by associated factors such as sinus disease or inflammation.

Can antifungal treatment improve headaches?

In some cases, yes—if symptoms are linked to fungal-related inflammation. However, antifungals can also occasionally cause headaches as a side effect.

Are “histamine-type” headaches part of aspergillosis?

Some patients describe symptoms in this way, but the underlying mechanism is often more complex than histamine alone.

Why do my headaches change over time?

This is common and may reflect changes in inflammation, treatment, sleep, or overall health.

When to seek medical advice

You should seek medical advice if you experience:

  • new or unusually severe headaches
  • headaches that are worsening over time
  • neurological symptoms (e.g. vision changes, weakness, confusion)
  • fever, neck stiffness, or other concerning symptoms

If you are unsure whether your headaches are related to aspergillosis, treatment, or another cause, it is important to discuss this with your healthcare team.

Summary

Headaches in people with aspergillosis are usually caused by a combination of factors rather than a single issue.

The most common contributors include:

  • sinus involvement
  • immune and inflammatory responses
  • sleep disturbance
  • medication effects

Understanding patterns and changes over time can be helpful, but medical assessment is important if symptoms are new, severe, or concerning.

Author and review

Prepared for: aspergillosis.org

Audience: Patients and non-specialist readers

Important: This article is for general information only and does not replace individual medical advice.

References

  1. Patterson TF et al. (2016). Practice Guidelines for the Diagnosis and Management of Aspergillosis.
    PMID: 27365388
  2. Denning DW et al. (2016). Chronic pulmonary aspergillosis guidelines.
    PMID: 26699723
  3. Chakrabarti A et al. (2009). Fungal sinusitis: a categorization and definitional schema.
    PMID: 19522756